Markus Barden

This paper validates a multicenter preclinical strategy for CAR T cells, demonstrating its feasibility in confirming CCR8 overexpression benefits across multiple centers.

This paper develops DROP-CARs, drug-regulated CAR-T cells that control cell-cell interactions using small-molecule switches, showing in vitro and in vivo functionality.

This paper develops antigen-dextramers to stain and functionally assess CAR T cells, showing they enable both detection and activation analysis with adjustable antigen density.